Antibody-drug conjugates (ADCs) represent an important class of cancer therapies that have
revolutionized the treatment paradigm of solid tumors. To date, many ongoing studies of …

Bladder cancer remains a leading cause of cancer death worldwide and is associated with
substantial impacts on patient quality of life, morbidity, mortality, and cost to the healthcare …

Background No treatment has surpassed platinum-based chemotherapy in improving
overall survival in patients with previously untreated locally advanced or metastatic …

Nectin-4 (Nectin cell adhesion molecule 4), a type I transmembrane cell adhesion protein,
was demonstrated to be overexpressed in a variety of tumors, making it an attractive antigen …

Despite recent advances, advanced-stage urothelial carcinoma (aUC) remains incurable,
with 5-year survival rates of approximately 10%. Platinum-based chemotherapy has a major …

Introduction Since 2016, the progressive use of immune checkpoint inhibitors (ICIs) starting
from second-line treatment has led to an improvement in overall survival in locally advanced …

Background IMvigor130 demonstrated statistically significant investigator-assessed
progression-free survival benefit with first-line atezolizumab plus platinum-based …

The treatment of metastatic urothelial carcinoma has dramatically changed over the past
decade with the approval of several therapies from multiple drug classes including immune …

Simple Summary For metastatic urothelial cancer (UC), platinum-based chemotherapy and
immunotherapy are used, with newer treatments like monoclonal antibodies (eg …

Urothelial carcinoma (UC) is a prevalent malignant tumor involving the urinary system.
Although there are various treatment modalities, including surgery, chemotherapy, and …